Curis Provides Third Quarter 2024 Business Update

Core Viewpoint - Curis, Inc. is making significant progress in its clinical programs, particularly with emavusertib, an IRAK4 inhibitor, showing promising results in combination therapies for various cancers, setting a positive outlook for 2025 [2][3]. Clinical Developments - Emavusertib demonstrated efficacy in a study involving patients with relapsed/refractory primary central nervous system lymphoma (PCNSL), with 3 complete responses and 1 unconfirmed complete response among 10 evaluable patients [3]. - The company plans to present additional clinical data from the TakeAim Leukemia study at the upcoming ASH annual meeting [4][5]. Financial Performance - For Q3 2024, Curis reported a net loss of $10.1 million, or$1.70 per share, an improvement from a net loss of $12.2 million, or$2.13 per share, in Q3 2023 [6]. - Revenues for Q3 2024 were $2.9 million, slightly up from$2.8 million in the same period last year, primarily from royalty revenues [7]. - Research and development expenses decreased to $9.7 million in Q3 2024 from$10.4 million in Q3 2023, attributed to lower consulting and employee-related costs [8]. Cash Position - Following a recent offering, Curis's cash and cash equivalents totaled $31.6 million, which is expected to support operations into mid-2025 [11].